Property	Value
Status
Version
Ad File
Disable Ads Flag
Environment
Moat Init
Moat Ready
Contextual Ready
Contextual URL
Contextual Initial Segments
Contextual Used Segments
AdUnit
SubAdUnit
Custom Targeting
Ad Events
Invalid Ad Sizes

featured

Published in Von Hippel-Lindau Disease and

Expert Opinion / Interview · May 14, 2018

Consequences of VHL Loss

Interview by

Farzanna S Haffizulla MD, FACP, FAMWA

Interview with

Kimryn Rathmell MD, PhD

Save Recommend

Sign in to PracticeUpdate

Only registered members have full access to PracticeUpdate content.

Sign in

Not a member?

Join for free

Additional Info

Disclosures

Disclosure statements are available on the authors' profiles:

Kimryn Rathmell MD, PhD

featured

2024 Top Story in von Hippel-Lindau Disease: Belzutifan for Treatment of Pancreatic Neuroendocrine Tumors

Commentary · December 11, 2024
featured

Prevalence and Economic Burden of von Hippel–Lindau Disease–Associated CNS Hemangioblastomas and Pancreatic Neuroendocrine Tumors in the US

Orphanet J Rare Dis · August 28, 2024
featured

Prognostic Factors Associated With VHL-Related Pancreatic Neuroendocrine Tumors

J. Clin. Endocrinol. Metab. · July 08, 2024
featured

Classification of 164 Challenging VHL Variants Based on Genotype–Phenotype Correlation

J. Med. Genet. · July 08, 2024
featured

ASCO 2024: Abstract Recommendations From Dr. Amit Tirosh for von Hippel–Lindau Disease

Conference Coverage · May 29, 2024
story of the week

Belzutifan for von Hippel–Lindau Disease–Associated Pancreatic Lesions

Clin. Cancer Res · April 26, 2024
story of the week

Inter- and Intra-Tumor Heterogeneity of Genetic and Immune Profiles in Inherited Renal Cell Carcinoma

Cell Rep · February 27, 2024
featured

Supratentorial Collision Tumor of Hemangioblastoma and Metastatic Clear Cell Renal Cell Carcinoma in a Patient With von Hippel–Lindau Disease

Case Rep Oncol · January 08, 2024
featured

2023 Top Story in von Hippel–Lindau Disease: Guidelines for the Surveillance of Patients With von Hippel–Lindau Disease

Commentary · December 18, 2023
featured

68Ga-DOTANOC PET/CT for Screening for and Surveillance of von Hippel–Lindau Disease

Nucl Med Mol Imaging · December 11, 2023
story of the week

Outcomes of and Indications for Renal Transplantation in Patients With von Hippel–Lindau Disease

Urol. Oncol · December 05, 2023

Renal Cell Carcinoma

Consequences of VHL Loss

Additional Info

Further Reading

2024 Top Story in von Hippel-Lindau Disease: Belzutifan for Treatment of Pancreatic Neuroendocrine Tumors

Prevalence and Economic Burden of von Hippel–Lindau Disease–Associated CNS Hemangioblastomas and Pancreatic Neuroendocrine Tumors in the US

Prognostic Factors Associated With VHL-Related Pancreatic Neuroendocrine Tumors

Classification of 164 Challenging VHL Variants Based on Genotype–Phenotype Correlation

ASCO 2024: Abstract Recommendations From Dr. Amit Tirosh for von Hippel–Lindau Disease

Belzutifan for von Hippel–Lindau Disease–Associated Pancreatic Lesions

Inter- and Intra-Tumor Heterogeneity of Genetic and Immune Profiles in Inherited Renal Cell Carcinoma

Supratentorial Collision Tumor of Hemangioblastoma and Metastatic Clear Cell Renal Cell Carcinoma in a Patient With von Hippel–Lindau Disease

2023 Top Story in von Hippel–Lindau Disease: Guidelines for the Surveillance of Patients With von Hippel–Lindau Disease

68Ga-DOTANOC PET/CT for Screening for and Surveillance of von Hippel–Lindau Disease

Outcomes of and Indications for Renal Transplantation in Patients With von Hippel–Lindau Disease

Related Videos